Hitting the Bullseye With Anti-BCMA Treatment – An In The Clinic Activity

Hitting the Bullseye With Anti-BCMA Treatment – An In The Clinic Activity is organized by Integrity Continuing Education Inc..,Release date: 29- 09- 2022,Expiration date: 29-09- 2023,Description:,Program Overview:,Although the survival of patients with multiple myeloma (MM) has drastically improved over the last two decades due to advances in treatment, the disease remains incurable and patients relapse several times. These patients may be relapsed or refractory (RR) to multiple lines of therapy. A relatively new class of agents that target B-cell maturation antigen (BCMA), which is highly expressed on the surface of myeloma cells, has made significant progress.,Currently, there are 3 BCMA-directed therapies for RRMM: one antibody drug conjugate (ADC) and two chimeric antigen-receptor T cell (CAR T) agents. Each offers distinct advantages and benefits. The ADC is an “off the shelf” treatment option that does not require collection and manufacturing, which can be advantageous for patients that have aggressive disease or that cannot tolerate the pretreatment conditioning. Both CAR T agents utilize a collection and manufacturing process that can take several weeks, even if the facility is available immediately. Patients may require bridging therapy during the interim.,While these new treatments offer more options for this group of patients, treatment selection can be challenging, necessitating consideration of disease-related and patient-related factors, such as disease morbidity (eg, refractory disease, renal impairment, extramedullary disease, or aggressiveness of disease in general), age and frailty (eg, performance status, disability), comorbidities, and cytogenetics.,This activity will provide insight and guidance from the experts in multiple myeloma and will address the challenges experienced in clinical practice.,Learning Objectives:,Upon completion of this educational activity, participants should be able to:,• Assess patients and select appropriate therapy based upon patient (comorbid conditions, proximity to treatment center, personal preferences) and disease characteristics (aggressiveness, stage, etc),• Incorporate multidisciplinary strategies to provide optimal care and management of treatment-related side effects.,,Additional details will be posted as soon as information is available.